Appendix 4C - quarterly
Melbourne, July 24, 2019 AEST (ABN Newswire) - Bluechiip Limited (Bluechiip or the Company) (
ASX:BCT) today released its quarterly cash flow report for the quarter ended 30 June 2019.
Business highlights
- A record quarter with net sales revenue of $517k (unaudited) from the delivery of readers, chips, software and services. The previous record net sales revenue, $272k, occurred in the March 2019 quarter.
- Total net sales for FY 2019 of $1.02 million (unaudited), an increase of 82% on the sales of $562k achieved in FY 2018.
- Scaling activities progressed well as the company continued to meet customer orders.
- Continued to pursue partnerships from the pipeline of developer kits and agreements in market.
- Received $187k from the Australian Government for the final portion of 2017/2018 Research & Development (R&D) Tax Incentive registration.
- Received $48k Export Marketing Development Grant (EMDG) from Austrade.
- Cash balance stands at $3.877m as at 30 June 2019 with no borrowings.
To view the report, please visit:
http://abnnewswire.net/lnk/0OHVM112
About Bluechiip Limited
Bluechiip Ltd (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.
Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.
Bluechiip: Delivering confidence in every sample.
| ||
|
